

**AD**\_\_\_\_\_

**AWARD NUMBER:** W81XWH-16-1-0284

**TITLE:** Development of New Therapeutics Targeting Biofilm Formation by the Opportunistic Pulmonary Pathogens *Pseudomonas aeruginosa* and *Aspergillus Fumigatus*

**PRINCIPAL INVESTIGATOR:** Lynne Howell

**RECIPIENT:** Hospital for Sick Children  
Toronto M5G 1X8

**REPORT DATE:** October 2017

**TYPE OF REPORT:** Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

<b>REPORT DOCUMENTATION PAGE</b>			<i>Form Approved</i> OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
<b>1. REPORT DATE</b> October 2017		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 15 Sep 2016 - 14 Sep 2017	
<b>4. TITLE AND SUBTITLE</b>  <i>Development of New Therapeutics Targeting Biofilm Formation by the Opportunistic Pulmonary Pathogens Pseudomonas aeruginosa and Aspergillus Fumigatus</i>			<b>5a. CONTRACT NUMBER</b> W81XWH-16-1-0284		
			<b>5b. GRANT NUMBER</b> PR150786		
			<b>5c. PROGRAM ELEMENT NUMBER</b>		
<b>6. AUTHOR(S)</b>  Lynne Howell  E-Mail: howell@sickkids.ca			<b>5d. PROJECT NUMBER</b>		
			<b>5e. TASK NUMBER</b>		
			<b>5f. WORK UNIT NUMBER</b>		
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Hospital for Sick Children    55 University Avenue Toronto ON M5G 1X8 Canada			<b>8. PERFORMING ORGANIZATION REPORT</b>		
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>		
			<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>		
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> The bacterium <i>Pseudomonas aeruginosa</i> (PA) and fungus <i>Aspergillus fumigatus</i> (AF) are common causes of pulmonary disease in immunocompromised patients. During infection, both microorganism form a biofilm, which includes exopolysaccharides Pel and Psl (PA) or galactosaminogalactan (AF). PelA, PslG, Sph3 and Ega3 are recently discovered glycoside hydrolases that disrupt PA and AF biofilms <i>in vitro</i> . Our aim is to demonstrate that these enzymes can be used to impair biofilm formation in the host tissues as well, therefore attenuating the infection. During this reported period, we have demonstrated that, <i>in vitro</i> , the enzymes impair the development of normal biofilm both in static culture and in a fluid biofilm culture system, and that they potentiate the action of antibiotics directed at PA or at AF. We have also demonstrated that, when injected intratracheally in mice, the hydrolases did not induce adverse immune reaction, nor did they induce any tissue damage to the host. Pharmacokinetics of the hydrolases in lungs is being assessed, first results showing that Ega3 and PslG persist longer than 12h and 72h, respectively, while Sph3 and PelA are degraded in under 12h.					
<b>15. SUBJECT TERMS</b> Pseudomonas aeruginosa; Aspergillus fumigatus; virulence; biofilm; exopolysaccharide; glycoside hydrolase; antimicrobial potentiation.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b> Unclassified	<b>b. ABSTRACT</b> Unclassified	<b>c. THIS PAGE</b> Unclassified	Unclassified	39	USAMRMC
			<b>19b. TELEPHONE NUMBER (include area code)</b>		

## TABLE OF CONTENTS

	<u>Page No.</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	6
4. Impact	27
5. Changes/Problems	29
6. Products	32
7. Participants & Other Collaborating Organizations	35
8. Special Reporting Requirements	37
9. Appendices	38

- 1. INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

The bacteria *Pseudomonas aeruginosa* (PA) and fungus *Aspergillus fumigatus* (AF) are common causes of pulmonary disease in immunocompromised patients. These infections are associated with high morbidity and mortality, underscoring the urgent need for new effective therapies for these conditions. During pulmonary infection, both pathogens form biofilms, which enhance resistance to antimicrobials and immune defenses. Biofilm formation is dependent on the synthesis of matrix exopolysaccharides – Pel, Psl for PA, galactosaminogalactan (GAG) for AF. Exopolysaccharide-deficient mutants of PA and AF are less virulent in animal models, suggesting that these glycans are promising therapeutic targets. We have identified and produced recombinant versions of microbial glycoside hydrolase (GH) enzymes, PelA<sub>h</sub>, and PslG<sub>h</sub> from PA and Ega3<sub>h</sub>, and Sph3<sub>h</sub> from AF, which degrade exopolysaccharides and disrupt biofilms *in vitro*. We hypothesize that treatment with these GHs alone or in combination with antimicrobials will be well tolerated and improve outcomes in experimental pulmonary infection with PA and AF. We therefore propose the following studies: (1) To characterize the ability of recombinant GH enzymes to enhance the activity of antimicrobial agents against PA and AF *in vitro* (2) Perform tolerability and pharmacokinetic studies of intratracheal therapy with recombinant GH in mice. (3) Evaluate the efficacy of GH therapy alone and in combination with antimicrobials for the treatment of acute and chronic PA and AF infection mouse models. In the short term these studies will provide solid preliminary data for the preclinical evaluation of pulmonary GH therapy against two of the most important opportunistic pulmonary pathogens. In the long-term, these results can also be extended to develop GH therapy pulmonary infections with other exopolysaccharide-producing pathogens such as *Staphylococcus*, *Acinetobacter* and *Mucor* species.

**KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

*Pseudomonas aeruginosa*; *Aspergillus fumigatus*; virulence; biofilm; exopolysaccharide; glycoside hydrolase; antimicrobial potentiation.

- 2. ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

**What were the major goals of the project?**

*List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.*

Please note this is partnered award with research being performed at McGill University (PI: Sheppard) and The Hospital for Sick Children (PI: Howell). The material presented herein pertains to both awards. Award numbers: W81XWH-16-1-0283 and W81XWH-16-1-0284

#### MAJOR GOALS FOR YEAR 1:

**Specific Aim 1:** To characterize the ability of the hydrolases to enhance the activity of antimicrobial agents in vitro.

**Major Task 1: Identify antimicrobials that are potentiated in the presence of candidate hydrolases.**

**Subtask 1:** Express and purify Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 1-3 (Months 1-9). (PI: Howell)

**Subtask 2:** Test Sph3<sub>h</sub>, PelA<sub>h</sub> and Ega3<sub>h</sub> in checkerboard combinations with antifungals against *A. fumigatus* biofilms (Months 1-9). (PI: Sheppard)

**Subtask 3:** Test PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> in checkerboard combinations with antibiotics against *P. aeruginosa* biofilms (Months 1-9). (PI: Howell)

**Subtask 4:** Test candidate hydrolase-antimicrobial combinations in an in vitro fluid biofilm culture model system (Months 6-12). (PI: Howell and Sheppard)

**Milestone:** *Identification of hydrolase-antimicrobial combinations that synergize against A. fumigatus and P. aeruginosa. These antimicrobials will be prioritized and used in Aim3.*

**Specific Aim 2:** To perform preliminary tolerability and pharmacokinetic studies of candidate hydrolases in vivo.

**Major Task 2: Test candidate hydrolases for toxicity in vivo.**

**Subtask 1:** Submit documents for Animal use approvals (Months 1-6). (PI: Sheppard)

**Milestone:** *obtain animal use approvals.*

**Subtask 2:** Express and purify recombinant PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 3 - 4 (Months 6-12). (PI: Howell)

**Subtask 3:** Test toxicity of pulmonary administration of hydrolase combinations (PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> combinations) in immunocompetent mice [10 mice per group X 4 experimental groups X 2 hydrolase regimens; 1 group of 10 untreated mice. All performed in duplicate = 180 mice] (Months 6-12). (PI: Sheppard)

**Subtask 4:** Test toxicity of pulmonary administration of hydrolases (PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> combinations) in immunocompromised mice [10 mice per group X 4 experimental groups X 2 hydrolase regimens; 1 group of 10 untreated mice. All performed in duplicate = 180 mice] (Months 6-12). (PI: Sheppard)

**Milestone:** *Evaluation of pulmonary toxicity of candidate hydrolase regimens.*

### **Major Task 3: Pharmacokinetic studies of candidate hydrolases**

**Subtask 1:** Express and purify Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 2 - 5 (Months 6-12). (PI: Howell)

**Subtask 2:** Test pharmacokinetics of hydrolases (Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub> / Ega3<sub>h</sub> combinations) in immunocompetent mice [25 mice per group (5 per time point) X 5 hydrolase therapies; 1 group of 25 untreated mice. All performed in duplicate = 300 mice] (Months 6-12). (PI: Sheppard)

**Subtask 3:** Test pharmacokinetics of hydrolases (Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/ Ega3<sub>h</sub> combinations) in immunocompromised mice [25 mice per group (5 per time point) X 5 hydrolase therapies; 1 group of 25 untreated mice. All performed in duplicate = 300 mice] (Months 6-12). (PI: Sheppard)

**Subtask 4:** Determine concentrations of candidate hydrolases and their combinations using animal tissue samples. (Months 6-12). (PI: Howell)

**Milestone:** *Evaluation of pharmacokinetics of candidate hydrolase regimens.*

### **What was accomplished under these goals?**

*For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.*

### **Accomplishments for Year 1:**

**Specific Aim 1** To characterize the ability of the hydrolases to enhance the activity of antimicrobial agents in vitro.

**MAJOR TASK 1** Identify antimicrobials that are potentiated in the presence of candidate hydrolases.

**Subtask 1:** Express and purify Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 1-3. Dr Howell's lab. SOW Time period: Months 1-9. Completion level = 100%.

#### **Background:**

Before the initiation of the grant, our labs were able to produce the GHs Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> in an *E. coli* expression system. This method reliably provides sufficient amounts of GH for *in vitro* experiments. However, *in vivo* experiments, as planned per SOW, require the production of substantial quantities of pure endotoxin-free protein. Therefore, we switched production from our standard *E. coli* system to either the endotoxin free *E. coli* bacterial system ClearColi<sup>®</sup> or to the *Pichia pastoris* yeast system PichiaPink<sup>®</sup>. To optimize the GH production we assayed multiple culture conditions.

## Developments:

### 1- GH production in bacterial system.

#### *Methodology:*

In our original protocol the GH coding sequence was cloned into a vector that allows the proteins to be produced with a histidine tag; after cell growth the culture supernatant was harvested and buffered at pH 8; finally, the GHs were purified using nickel affinity and size exclusion chromatography. The production of the Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> GHs has been attempted and subsequently optimized in the bacterial system ClearColi<sup>®</sup>.

#### *Optimization of Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> expression:*

Successful optimization efforts involved: growth in both richer, and autoinduction media; growth in Fernbach flask and higher shaking speeds to improve aeration of rich media.

These changes in protocol allowed an increase in the production of GHs up to 8 times, as compared to the original production. Final yields were 125 mg of Sph3<sub>h</sub> / liter of culture medium, and more than 80 mg of PelA<sub>h</sub>, and PslG<sub>h</sub> (Table 1), which will be more than adequate for our needs for *in vivo* assays.

<b>Protein</b>	<b>Media &amp; Volume (L)</b>	<b>Protein Yield (mg)</b>	<b>Protein Yield (mg) / Media Volume (L)</b>	<b>Protein Yield (mg) / Cell weight (g)</b>
<b>Sph3</b>	Luria Broth (LB), 3L	84mg	28	8
	LB, 2L	36mg	18	6.8
	Terrific Broth (TB), 1L, fernbach	125mg	125	19.3
<b>PelA</b>	LB, 4L	94.57mg	24	9.8
	LB, 2L	35.52mg	17.8	7.4
	TB , 1L, fernbach	84.15mg	84.2	17.4
<b>PslG</b>	LB, 4L	32.3mg	8	3.8
	TB, 2L	28.9mg	14.4	6.6
	Autoinduction, 0.5L, fernbach	41.48mg	83	10.5

Table 1. Optimization of GH production in *E. coli*. For each GH, the first line represents the original protocol; the following lines represent optimization progress.

While the optimization proved effective for Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub>, we were unable to produce soluble Ega3<sub>h</sub> in *E. coli* and therefore optimization of this GH was performed in the PichiaPink<sup>®</sup> yeast system.

### 2- Ega3<sub>h</sub> production in yeast system.

Originally, we had proposed to move the production of Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> to *P. pastoris*, and the first steps of this transfer have been successfully performed, as mentioned in “Technical Report of Year 1- Quarter 2”. With the improvements to the *E. coli* ClearColi® production protocol (described above), we decided to keep Sph3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> production in the bacterial system. Only optimization of Ega3<sub>h</sub> production has been undertaken in *P. pastoris*.

**Methodology:**

The gene sequence was modified by codon optimization to maximize the protein expression, and cloned in pPink $\alpha$ -HC plasmid (Invitrogen) under the control of the *AOX1* promoter for induction in the presence of methanol (Figure 1). A N-terminal alpha-factor secretion signal was also added to the protein. The construct was used to transform a *P. pastoris* strain which lacks the *ade2* gene; transformants able to grow on a medium without adenine were screened for integration of the vector in the yeast genome. In successful transformants, after translation, the N-terminal alpha-factor secretion signal allows Ega3<sub>h</sub> to be secreted into the yeast growth media. Culture supernatant was therefore harvested, filtered and buffered at pH 8 and the protein purified using ammonium sulfate precipitation, followed by size exclusion chromatography.

This method yielded ~ 2.5 mg of Ega3<sub>h</sub> for every 1 L of growth.





Figure 1. Genetic map of the vector used for expression of GHs in *P. pastoris*. The coding sequence of the desired GH (red) was cloned after the N-terminal alpha-factor secretion signal ( $\alpha$ -factor). It is therefore placed under control of the *AOX1* promoter (*P<sub>AOX1</sub>*) and *cyc1* terminator. A *ade2* cassette serves as a marker for the selection of successful transformants.

**Optimization of Ega3<sub>h</sub> expression (Figure 2):**



To optimized the expression we systematically explored: growth at higher shaking speed to improve aeration; stepwise expression: starvation of the cells; acclimation to methanol by addition of small amounts; addition of more methanol to start protein expression; addition of a second round of expression, transferring cells to new expression media; decreasing the pH of the media to pH6 to reduce degradation of Ega3<sub>h</sub> (data not shown).

**Old Protocol**



**New Protocol**




Figure 2. Schematic comparison of the old and new GH production methods in *P. pastoris*.

**Results:**

The improvements in protocol increased the yield of the protein by 4 fold to a final yield of 8 mg of protein / liter of culture medium (Table 2).

Protein	Media pH	Growth Volume (L)	Expression Volume (L)	Protein Yield (mg)	Protein Yield (mg) / Growth Volume (L)
Ega3 <sub>h</sub>	7	5.8L	2.9L	8.6mg	1.5
	7	6L	3L	10.3mg	1.7
	7	2L	2L	13.0mg	6.5
	6	4L	2L	31.6mg	7.9
	6	4L	4L	46.5 mg	11.6

Table 2. Optimization of GH production in *P. pastoris*. The first line represents our original protocol.

**3- Control of GH quality:** The activity of each enzyme is checked and quantified using our standard biofilm assays prior to their use in Subtasks 2-3. To assess whether there were any negative impacts to the enzyme as a consequence of the changes in the expression/purification protocol, we assayed the activity of the GHs using our biofilm disruption assay: The results revealed similar biofilm disruption activity throughout the protocol modifications (data not shown).

**Subtask 2:** Test Sph3<sub>h</sub>, PelA<sub>h</sub> and Ega3<sub>h</sub> in checkerboard combinations with antifungals against *A. fumigatus* biofilms. Dr Sheppard's lab. SOW Time Period: Months 1-9. Completion level = 100%.

**Background:** Our preliminary data had reported that GH treatment enhanced the *in vitro* activity of the antifungal posaconazole against AF. We proposed to expand these studies to test other antifungal agents, and perform checkerboard studies to examine the effects of varying GH concentration on antifungal activity.

**Accomplishments:**

**Methodology:** Antifungal effects on AF were measured by quantifying metabolic activity using the well-described XTT assay. Briefly, *A. fumigatus* biofilms were pre-grown at 37°C for 9 h in RPMI media in 24 well plates; after which a gradient of antifungal drug was added to the wells in the presence or absence of 0.5 μM of the indicated GH. Plates were incubated for an additional 15 h and fungal viability was then measured using the XTT metabolic assay. The MIC<sub>50</sub> was defined as the minimum concentration of antifungal required to inhibit fungal metabolism by 50%.

Fungal inhibition was also scored visually in accordance with the guidelines stipulated by the Clinical and Laboratory Standards Institute (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi (Figure 3). In this assay, 1x10<sup>4</sup> conidia of strain Af293 were added to 96-well plates containing the GH-antifungal combination of interest and incubated for 24 h at 37°C, 5% CO<sub>2</sub>. Plates were then examined microscopically and the minimum inhibitory concentration required for a 90% reduction in fungal growth (MIC<sub>90</sub>) was recorded. As per CLSI guidelines, for the echinocandin caspofungin, the minimum effective concentration (MEC) resulting in a significant change in morphology was used rather than growth inhibition. For each combination of antifungal/GH, at least 3 independent experiments were performed.

Originally, we had planned to study voriconazole as a representative of the azole class of antifungals; however, since its antifungal activity was not potentiated by GHs, it was replaced by posaconazole in all subsequent assays.




Figure 3. Example of visual scoring. Red boxes indicate the MIC<sub>90</sub>. The changes in MIC<sub>90</sub> highlight the significantly increased antifungal activity of posaconazole in the presence of Sph3<sub>h</sub>.

**Results:** MIC assay by XTT is a widely used method for measuring cell metabolic activity. However, in direct comparisons of the XTT metabolic assay with visual/fungal biomass growth studies, we observed that GH treatment resulted in artificially high metabolic readings in viable fungi. This observation likely reflects enhanced reagent penetration into exopolysaccharide-deficient hyphae following GH treatment (see section “4. IMPACT” and “5. CHANGES /PROBLEMS”). We therefore elected to replace the XTT metabolic assay with visual scoring of the inhibitory effect of drugs, in absence or presence of GH.

1- Results with a fixed concentration of GH: Initial studies demonstrated that 0.5  $\mu$ M of all 4 GHs, potentiates the inhibition of fungal growth by drugs of the 3 licensed classes of antifungals: polyenes (amphotericin B), azoles (posaconazole) and echinocandins (caspofungin) (Figure 4).




Figure 4: Impact of addition of 0.5  $\mu$ M of GHs on the MIC<sub>50</sub> of antifungal drugs. The combination of caspofungin/PslG<sub>h</sub> was not included in these initial screening assays but has been evaluated in the full checkerboard assays (Figure 5). \* indicates a statistically significant difference compared to drug alone (p < 0.05).

## 2- GH-antifungal checkerboard assays

All GH/antifungal combinations demonstrated efficacy against *A. fumigatus* with the exception of the Amphotericin B/PelA combination (Figure 5). A GH concentration of 100 nM appears to be the minimum effective concentration to reduce MIC values for the majority of combinations. The most effective (based on overall MIC value reduction) GH/antifungal combinations tested were posaconazole/Sph<sub>3h</sub> and caspofungin/PelA<sub>h</sub>, and these combinations will be therefore be prioritized for further studies *in vivo*.

Posaconazole-Sph3			Amphotericin B-Sph3			Caspofungin-Sph3		
		MEC			MEC			MEC
Hydrolase conc. (nM)	0	0.500	Hydrolase conc. (nM)	0	0.833	Hydrolase conc. (nM)	0	0.500
	0.8	0.333		0.8	0.833		0.8	0.333
	4	0.333		4	0.667		4	0.333
	20	0.250		20	0.500		20	0.250
	100	0.208		100	0.500		100	0.167
	500	0.167		500	0.417		500	0.125

Posaconazole-Ega3			Amphotericin B-Ega3			Caspofungin-Ega3		
		MEC			MEC			MEC
Hydrolase conc. (nM)	0	0.375	Hydrolase conc. (nM)	0	0.667	Hydrolase conc. (nM)	0	0.583
	0.8	0.375		0.8	0.667		0.8	0.500
	4	0.375		4	0.667		4	0.333
	20	0.3125		20	0.500		20	0.250
	100	0.1875		100	0.500		100	0.208
	500	0.1875		500	0.500		500	0.208

Posaconazole-PelA			Amphotericin B-PelA			Caspofungin-PelA		
		MEC			MEC			MEC
Hydrolase conc. (nM)	0	0.500	Hydrolase conc. (nM)	0	0.667	Hydrolase conc. (nM)	0	0.833
	0.8	0.500		0.8	0.667		0.8	0.417
	4	0.500		4	0.667		4	0.333
	20	0.500		20	0.667		20	0.250
	100	0.417		100	0.667		100	0.208
	500	0.333		500	0.667		500	0.208

Figure 5. Minimal effective concentration (MEC) in  $\mu\text{g}/\text{mL}$  for posaconazole, amphotericin B and caspofungin as per visual scoring in a fungal inhibition assay in presence of GHs.

**Subtask 3:** Test PsIG<sub>h</sub>/PelA<sub>h</sub> and PsIG<sub>h</sub>/Ega3<sub>h</sub> in checkerboard combinations with antibiotics against *P. aeruginosa* biofilms. Dr Howell's lab. SOW Time Period: Months 1-9. Completion level = 50 %.

**Background:** Our preliminary studies indicated that GH treatment enhanced the antimicrobial activity of colistin. We sought to expand these studies to examine the effects of GH therapy on the activity of other antibiotics in checkerboard assays.

Accomplishments:

*Choice of an experimental model:*

During Year 1 Quarter 1-2 our lab had acquired the material and a vast general knowledge of the Calgary Biofilm Device (CBD), a method we aimed at using to fulfill this part of our work.

After preliminary assays, as explained in detail in the section "5. PROBLEMS /CHANGES", we concluded that this device is not fit for our experimental needs, and we developed an alternate protocol based on our standing biofilm tube assay. In this assay, bacteria are grown for 24 h and then subjected to GH + antibiotic combinations; following incubation, the biofilm is mechanically disrupted and the cells are enumerated using serial dilutions.

During Year 1 Quarter 3, we experienced some difficulties with reproducibility of the drug potentiation assay using our standing biofilm tube assay and therefore while continuing to develop a reliable assay, we also re-visited with the help of our collaborator Dr Parsek (University of Washington) optimizing the protocol for the Calgary Biofilm Device (CBD).

**Results:**

Using a 1 μM fixed concentration of PelA<sub>h</sub>/PsIG<sub>h</sub> on biofilms of *P. aeruginosa* PA01, that were grown for 24 h at 37°C, we were able to demonstrate significant potentiation of the antibiotics, tobramycin (an aminoglycoside), ciprofloxacin (a fluoroquinolone) and polymyxin. There was a positive effect for neomycin (another aminoglycoside) but the effect was not statistically significant (Figure 6).




Figure 6. Potentiation of antibiotics efficiency against *P. aeruginosa* by addition of a mix of GHs PelA<sub>h</sub>/PsIG<sub>h</sub> at a 1 μM concentration each. Several concentrations of antibiotics were used and the herein presented results represent the concentrations would gave the highest potentiation. \* indicates a significant decrease in CFU counting, with  $p \leq 0.05$  by ANOVA test.



**Subtask 4:** Test candidate hydrolase-antimicrobial combinations in an *in vitro* fluid biofilm culture model system. Dr Howell and Sheppard's labs. SOW Time Period: Months 1-6. Completion level = 25%

Accomplishments:

**Methodology:** We have successfully developed a method to grow AF under flow biofilm conditions. Briefly,  $1.5 \times 10^5$  conidia of RFP-expressing *A. fumigatus* strain Af293 were grown in Brian medium for 9 h. Young hyphae were scraped off, transferred to flow chambers, and incubated at 37°C for 2 h to allow the hyphae to adhere to the chamber surface. Biofilms were then allowed to develop for 24 h at 37°C under constant flow of 1% Brian medium. The resulting biofilms were then stained with FITC-conjugated soy bean agglutinin for GAG detection and imaged by confocal microscopy. Susceptibility of biofilms to GH therapy was evaluated by treating flow-grown biofilms with a 2  $\mu$ M of the GH of interest for 2 h prior to imaging.

**Results:** Hyphae stained strongly with SBA-FITC (green), suggesting that GAG is produced under flow conditions (Figure 7A). Consistent with the anti-GAG activity of PslG and Sph3h, GH-treated biofilms exhibited reduced SBA staining compared to the untreated sample. (Figures 7B, 7C)

**A. without GH**

**B. PslG-treated**

**C. Sph3-treated**




Figure 7. SBA-FITC staining of AF biofilms grown under flow conditions. A. Untreated AF biofilms. B. AF biofilms treated with 2  $\mu$ M of PslG<sub>h</sub>. C. AF biofilms treated with 2  $\mu$ M of Sph3<sub>h</sub>. Vertical Z-stacks were acquired to generate both top-down (top images) and side views (bottom images) for each sample.

**MAJOR TASK 2:** Test candidate hydrolases for toxicity *in vivo*.

**Subtask 1:** Submit documents for Animal use approvals. Dr Sheppard's lab. SOW Time Period: Months 1-6. Completion level = 100%

Accomplishments: IACUC protocol number #2016-7808, was approved by the USAMRMC Animal Care and Use Review Office (ACURO) on 18 Nov 2016. This protocol was previously approved by the McGill University IACUC on 01-JUN-2016.

**Subtask 2:** Express and purify recombinant PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 3 - 4 Dr Howell's lab. SOW Time Period: Months 6-12. Completion level = 100%.

As stated in Major Task 1 – Subtask 1, GH production in our lab is now routine and we can produce sufficient protein, both in quantity and quality (endotoxin-free enzyme, verified activity) to meet all requirements for the other subtasks of Major Task 2.

**Subtask 3:** Test toxicity of pulmonary administration of GH combinations (PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> combinations) in immunocompetent mice. Dr Sheppard's lab. SOW Time Period: Months 6-12. Completion level = 100%.

Background:

Preliminary studies in our labs indicated that administration of two doses of 0.75 µg Sph3<sub>h</sub> is well tolerated by immunocompromised mice. Our aim is to expand these studies to test of tolerability to all GHs, at dosage as high as 500 µg, administered as single or multiple doses, and in immunocompetent or immunocompromised mice. These studies are critical to guide dose selection for *in vivo* efficacy studies. Subtask 3 focuses on immunocompetent mice and subtask 4 uses immunocompromised animals.

Accomplishments:

*Methodology.* Recombinant GH enzymes alone and in combination were administered intratracheally at doses ranging from 1-500 µg. Mice were monitored for 7 days, then sacrificed to investigate the sign of pulmonary injury or inflammation. Pulmonary leukocyte recruitment was assessed by flow-cytometry performed on tissue homogenates and by histopathology.

**Results:**

1- GH monotherapy (PslG<sub>h</sub>, PelA<sub>h</sub>, Sph3<sub>h</sub>, Ega3<sub>h</sub>):

- GH treatment had no effect on mouse body weight and body temperature. (Figure 8, 9)




Figure 8. Monitoring of mouse temperature over 7 days after intratracheal injection of the indicated GH in PBS.




Figure 9. Monitoring of mouse weight over 7 days after intratracheal injection of the indicated GH in PBS.

- Pulmonary leukocyte recruitment: GH therapy was associated with minor increases in pulmonary macrophage numbers (Figure 10), particularly at high doses, suggesting that 500 µg may be the maximal unit dose deliverable to mice. Early experiments with Ega3 suggested a significant increase in pulmonary leukocyte recruitment at doses up to 100 µg. Although this observation could suggest that Ega3 may be less well tolerated than other GHs, these results



were obtained with a single preparation of this enzyme and repeat testing at a higher dose of 500 µg failed to reproduce this response. Repeat studies of lower dose Ega3 are ongoing to confirm the reproducibility of these observations.




Figure 10. Absolute quantification of leukocyte populations in mouse lungs as measured by flow-cytometry performed on lung homogenates. Lungs were harvested 7 days following treatment with a single dose of the indicated GH. \* indicates a significant difference with the untreated group with  $p \leq 0.05$  in ANOVA test.

- No differences between treated and untreated mice were detected by histological examination of pulmonary tissue sections (data not shown).
- Pulmonary injury: No differences in lactate dehydrogenase (LDH) release in the BAL fluid were observed between treated and untreated mice suggesting that GH therapy does not induce significant pulmonary injury (Figure 11).




Figure 11. Quantification of lactate dehydrogenase (LDH) activity in the bronchoalveolar fluid harvested from mice 7 days following treatment with a single dose of the indicated GH.

2- Therapy with GH combinations (PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub>): We have now completed two replicates of these experiments and the data are presented below.

- GH treatment had no effect on mouse body weight and body temperature. (Figure 12, 13)




Figure 12. Monitoring of mouse temperature over 7 days after intratracheal injection of the indicated GH combinations in PBS.




Figure 13. Monitoring of mouse weight over 7 days after intratracheal injection of of the indicated GH combinations in PBS.

- Pulmonary leukocyte recruitment: As with GH monotherapy a significant increase of alveolar macrophages was observed with both GH combinations at the low doses (Figure 14), although interestingly this increase was not observed at the higher combined dose of 250 µg of each GH. In contrast, this higher GH dose was the only one associated with increase in lymphocyte recruitment. No significant variation in recruitment of neutrophils and eosinophil was observed at any dose of GH combination. Collectively these data suggest that effects of GH therapy on pulmonary leukocyte population is not dose-dependent.




Figure 14. Absolute quantification of leukocyte populations in mouse lungs as measured by flow-cytometry performed on lung homogenates. Lungs were harvested 7 days following treatment with a single dose of the indicated GH combination.

- No differences between treated and untreated mice were detected by histological examination of pulmonary tissue sections (data not shown).
- No differences in lactate dehydrogenase (LDH) release in the BAL fluid were observed between treated and untreated mice (Figure 15).




Figure 15. Quantification of lactate dehydrogenase (LDH) activity in bronchoalveolar fluid harvested from mice 7 days following treatment with a single dose of the indicated GH combination.

**Subtask 4:** Test tolerability of pulmonary administration of hydrolase combinations (PslG<sub>h</sub>/ PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub>) in immunocompromised mice. Dr Sheppard's lab. SOW Time Period: Months 6-12. Completion level = 50%.

Accomplishments: We have completed the first experiment evaluating the tolerability of PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> (250 µg of each GH) in neutropenic mice.

- GH treatment had no effect on mouse body weight and body temperature
- No significant effects on pulmonary leukocytes populations was observed (Figure 16)




Figure 16. Absolute quantification of leukocyte populations in mouse lungs as measured by flow-cytometry performed on lung homogenates. Lungs were harvested 7 days following treatment with a single dose of the indicated GH combination.

- No differences between treated and untreated mice were detected by histological examination of pulmonary tissue sections (data not shown).
- No differences in lactate dehydrogenase (LDH) release in the BAL fluid were observed between treated and untreated mice (Figure 17).




Figure 17. Quantification of lactate dehydrogenase (LDH) activity in the bronchoalveolar fluid harvested from mice 7 days following treatment with a single dose of the indicated GH combination.

### **MAJOR TASK 3:** Pharmacokinetic studies of candidate hydrolases

**Subtask 1:** Express and purify Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub> for subtasks 2 - 5. Dr Sheppard's lab. SOW Time Period: Months 6-12. Completion level = 100%.

As stated in Major Task 1 – Subtask 1, GH production in our lab is now routine and we can produce sufficient protein, both in quantity and quality (endotoxin-free enzyme, verified activity) to meet all requirements for the other subtasks of Major Task 3. The necessity to change Ega3<sub>h</sub> production from *E. coli* to *P. pastoris* resulted in a delay in preparation of an anti-Ega3 antibody and the completion of subtasks 2, 4 and 5. Anti-Ega3 antibodies are now available and these studies are currently ongoing.

**Subtask 2:** Test pharmacokinetics of GHs (Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> combinations) in immunocompetent mice [25 mice per group (5 per time point) X 5 GH therapies; 1 group of 25 untreated mice. All performed in duplicate = 300 mice]. Dr Howell and Sheppard's labs. SOW Time Period: Months 6-12. Completion level = 50%.

#### Background:

Determining the pulmonary GH pharmacokinetics is critical for the design of efficacy studies. Polyclonal antibodies that recognize Sph3<sub>h</sub>, PelA<sub>h</sub> or PslG<sub>h</sub> have been previously produced by our group, however an anti-Ega3<sub>h</sub> antibody had not yet been generated. In this reporting period, we therefore produced and characterized a polyclonal anti-Ega3<sub>h</sub> in addition to performing animal experiments to characterize of the pulmonary half-life of recombinant GHs in mice.

#### Accomplishments:

- 1- Production and validation of an anti-Ega3<sub>h</sub> antibody.

#### Methodology:

Purified Ega3 was used to generate antiserum from rabbits. The polyclonal antibodies were produced by CedarLane Laboratories (Burlington, Ontario). The production of polyclonal anti-Ega3<sub>h</sub> antibodies was evaluated by Western blot using recombinant Ega3<sub>h</sub> with and without endoglycosylase (EndoH) treatment.

**Results:**

Serum from Ega3<sub>h</sub>-vaccinated rabbits recognizes both glycosylated and deglycosylated Ega3<sub>h</sub> (Ega3<sub>h</sub>, Ega3<sub>h</sub> + EndoH) *in vitro* (Figure 18). As indicated the antibody recognizes both forms of the protein.




Figure 18. Western-blot of endoglycosylase-H treated or untreated purified Ega3<sub>h</sub>, using rabbit anti-Ega3<sub>h</sub> antibody from the first bleed as a primary antibody, and goat-anti-rabbit-HRP antibody as a secondary. GH load was 1 µg per well and the antibody was diluted 1/1000

The terminal bleed confirmed the results observed with the first bleed (Figure 19). The anti-Ega3<sub>h</sub> antibody was thereafter tested against Ega3<sub>h</sub> as diluted in lung homogenate after tracheal injection in mice.




Figure 19. Western-blot of purified Ega3<sub>h</sub>, using rabbit anti-Ega3<sub>h</sub> antibody from terminal bleed as a primary antibody, and goat-anti-rabbit-HRP antibody as a secondary. GH load was 1 µg per well and the antibody was diluted 1/1000.


2- Validation of antibody specificity for detection of recombinant GHs in pulmonary tissue

**Methodology:** Mice were treated intratracheally with 500 µg of each GH. The mice were sacrificed and their lungs harvested at the indicated time points. Homogenized lungs samples were analyzed by western blot analysis to quantify GH concentrations using rabbit anti-GH antibodies. A goat-anti-rabbit-HRP antibody was used as the secondary antibody.


**Results:**

Western blot analysis showed that anti-GH antibodies detect recombinant GHs in pulmonary tissue (Figure 20).


**PeIA<sub>h</sub> (replicate #1)**




**PeIA<sub>h</sub> (replicate #2)**




**Sph3<sub>h</sub> (replicate #1)**



**Sph3<sub>h</sub> (replicate #2)**



### PslG<sub>h</sub> (replicate #1)



### Ega3<sub>h</sub> (replicate #1)




Figure 20. Western-blot of lung homogenates from lung harvested at 0, 12, 24, 36, 48 or 72h after intratracheal treatment with the indicated GH.

### 3- Pharmacokinetics of recombinant GHs (**Subtask 4**).

**Results:** Following a single 500 µg intratracheal dose, all GHs were detected in the lung immediately after therapy. Marked variation in the half-lives of individual GH proteins were observed, ranging from 3 to 30 hours (see Table 3)

Hydrolase	Sph3 <sub>h</sub>	PelA <sub>h</sub>	Ega3 <sub>h</sub>	PslG <sub>h</sub>
Estimated half-life	3h	4h	8h	30h

Table 3. Estimation of half-life of GHs in mouse lung after intratracheal injection of 500 µg of pure GH in PBS.

**Subtask 3:** Test pharmacokinetics of hydrolases (Sph3<sub>h</sub>, Ega3<sub>h</sub>, PelA<sub>h</sub> and PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub> combinations) in immunocompromised mice [25 mice per group (5 per time point) X 5 hydrolase therapies; 1 group of 25 untreated mice. All performed in duplicate = 300 mice. Dr Howell and Sheppard's labs SOW Time Period: Months 6-12. Completion level = 0%.

These studies will now be completed in months 13-19.

**Subtask 4:** Determine concentrations of candidate hydrolases and their combinations using animal tissue samples. Dr Howell's lab. SOW Time Period: Months 6-12. Completion level = 50%.

Results from this sub-task are presented in Figure 20 and Table 1.



**What opportunities for training and professional development has the project provided?**

*If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.*

Rachel Corsini and James Stewart were trained by Melanie Lehoux in regard of animal care. They therefore learned to perform intratracheal injection of GHs in mice, as well as mouse infection with pathogens. They also learned to isolate *P. aeruginosa* from lung tissues and monitor this population.

Brian Hicks, an undergraduate research assistant, was trained by Ira Lacdao in modern biochemical techniques, specifically protein expression and purification.

Natalie Bamford, Perrin Baker, Brendan Snarr presented their results in relation to this grant at several conferences, thus improving their presentation skills. Conferences were: Trends in Medical Mycology Congress, Belgrade, Serbia, October 2017; Canadian Glycobiology Network Symposium, Banff, Canada, May 2017; RI-MUHC IDIGH Research Day 2017, Montreal, Quebec, April 2017.

**How were the results disseminated to communities of interest?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.*

Results of our GH studies published in the Proceedings of the National Academy of Sciences (USA) were the subject of a numerous media interviews and reports including: CTV National and local television news as well as TéléQuébec: Les Electrons Libres; newspaper articles in Le Devoir and LaPresse; radio interviews on CBC and CJAD radio; and internet feature articles on CBC and RCI.net.

**What do you plan to do during the next reporting period to accomplish the goals?**

*If this is the final report, state "Nothing to Report."*

*Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.*

As per SOW, we will complete the unfinished subtasks on which work has been accomplished as described above. In parallel, we will perform the work described in subtasks that are related to the testing of GHs in animal models of acute disease (Major task 5), as well as chronic disease (Major Task 6). Briefly:

**Major Task 1 – Subtask 1:**

Protein production will continue to support other specific aims.

**Major Task 1 – Subtask 2:**

Complete.

**Major Task 1 – Subtask 3:**

Now that we have optimized the assay to show antibiotic potentiation against bacterial biofilm, we planned on performing 2-dimensional checkerboard assays using varying concentrations of drug and GH, in order to determine if potentiation is reproducible and which antibiotic shows the most promising potentiated antibacterial activity. The unexpected departure of PDF Perrin Baker in early June 2017 and the delay in recruiting his replacement has delayed in the completion of this task.

**Major Task 1 – Subtask 4:**

We will complete work in this aim by testing GH combinations and confirming the activity of posaconazole/Sph3<sub>h</sub> and caspofungin/PelA<sub>h</sub> against dynamically grown biofilms

**Major Task 2 – Subtask 1:**

Complete.

**Major Task 2 – Subtask 2:**

Complete.

**Major Task 2 – Subtask 3:**

Complete.

**Major Task 2 – Subtask 4:**

We will complete our duplicate testing of the tolerability of GHs in immunocompromised mice.

**Major Task 3 – Subtask 1:**

Complete

**Major Task 3 – Subtask 2:**

1) The pharmacokinetics of combination GH therapy (PslG<sub>h</sub>/PelA<sub>h</sub> and PslG<sub>h</sub>/Ega3<sub>h</sub>) will be tested in immunocompetent mice

2) Using western blot analysis as a gold standard we have begun to develop an ELISA for future pharmacokinetic analyses. To date we have established the ELISA protocol for PelA<sub>h</sub> and PslG<sub>h</sub> using purified protein, and are currently developing the ELISA assay for Sph3 and Ega3. These assays will be used in the preclinical development of the enzymes.

**Major Task 3 – Subtask 3:**

The assays outlined in Subtask 2 will be repeated in immunocompromised mice.

**Major Task 4 –**

Once we have defined the half-life of each GH we will evaluate the need for Major task 4 (modification of hydrolases).

**Major Task 5: Test GHs for activity in animal models of acute disease**

Has been initiated for completion by month 30.

**Major Task 6: Test GHs for activity in animal models of chronic disease**

To be initiated for completion by month 30.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

**What was the impact on the development of the principal discipline(s) of the project?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).*

Our demonstration that microbial GHs can disrupt biofilms has generated significant interest in the scientific community. A recent review in Nature Microbiology Reviews highlighted the potential of GH therapy and we have been invited to submit an editorial describing the potential of these therapeutics in the fight against antimicrobial resistant organisms.

**What was the impact on other disciplines?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.*

**XTT metabolic assay**

This assay is a commonly used method to study fungal biofilms and the activity of antimicrobial agents against biofilm-grown fungi. Our finding that loss of exopolysaccharide matrix can lead to artificially high metabolic readings suggests an important limitation to this assay that was previously unknown.

**What was the impact on technology transfer?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:*

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

The results of the studies described in this report add value to our existing intellectual property and patent describing the use of microbial GHs as anti-biofilm therapeutics.

**What was the impact on society beyond science and technology?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:*

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report

5. **CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:

**Changes in approach and reasons for change**

*Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.*

No significant changes beyond the minor modifications to experimental techniques detailed below.

**Actual or anticipated problems or delays and actions or plans to resolve them**

*Describe problems or delays encountered during the reporting period and actions or plans to resolve them.*

**Major Task 1 –Subtask 2:**

XTT metabolic assay is the method we originally planned to use for measuring antifungal drug potentiation by GHs. This assay is a colorimetric assay that relies on intracellular penetration of the XTT reagent into the fungi where it is metabolized. Due to the loss of hyphal exopolysaccharide due to GH treatment, uptake of the XTT reagent by fungi is enhanced, leading to artificially high metabolic readings in the presence of GH enzymes. Therefore, the XTT assay has a limited range of reliability and accuracy. We have therefore elected to use visual scoring of the inhibitory effect of drugs, in absence or presence of GH. Visual scoring is performed as per CLSI (Clinical & Laboratory Standards Institute) guidelines in a blinded fashion.

**Major Task 1 – Subtask 3:**

1) Progress on this task was delayed due to the unanticipated departure of postdoctoral fellow Perrin Baker (Howell Lab) in early June 2017. After advertising the position and interviewing candidates, Dr. Raju was recruited and joined the Howell Lab on September 12, 2017. Completion of these studies has been a priority for Dr. Raju since her recruitment.

2) Antibiotic Potentiation

Despite expertise using the Calgary Biofilm Device (CBD) we have concluded that this device is not suited for the proposed experiments: the CBD is used to qualitatively determine the amount of antibiotic required to kill cells in a biofilm state; this means that all biofilm biomass must be removed from the 96 polystyrene pegs into a 96-well plate, as the plate is read for bacterial growth. Unfortunately, the biofilms produced in the lab cannot easily and consistently be removed from pegs, thus leading to inconsistent results. From other antibiotic potentiation assays we have also

found that optimal antibiotic potentiation occurs at an antibiotic concentration that is sufficiently high to kill planktonic (free-swimming cells) but not biofilm embedded bacterial cells.

To overcome the CBD issues and with the knowledge we have gained from other experiments, we have moved to using a standing biofilm tube assay, previously published in our 2016 Science Advances paper. Our aim was to test antibiotic concentrations which show 1 log or more killing and use these concentrations with a single dose of each enzyme combination that is sufficient to disrupt the biofilm. This methodology was supposed to increase both the feasibility and the reproducibility of the assay.

While we continued to develop the protocol for the drug potentiation assays using our standing biofilm tube assay, we also decided to re-visit and optimize our Calgary Biofilm Device protocol. With the help of our collaborator Dr Parsek (University of Washington), we were able to increase biofilm formation, and results from Dr. Parsek's lab, using fixed concentration of PelA<sub>h</sub>/PslG<sub>h</sub> on biofilms of *P. aeruginosa* PA01 are encouraging that this method is now functional in our hands. We now need to transfer the protocol developed by Dr. Parsek and reproduce these results in house and therefore will continue to explore the use of the CBD and our standard biofilm assay to complete the potentiation experiments outlines.

### 3) Choice of *P. aeruginosa* strain for *in vivo* and *in vitro* studies.

We had proposed to test several *P. aeruginosa* strains that produce different biofilm polysaccharide profiles. PA14 strain was selected to represent strains which have been reported to produce Pel. However, work from our group has now demonstrated that although PA14 makes abundant Pel-dependent biofilms at 25°C, biofilm formation is significantly reduced at 37°C likely due to a marked reduction in Pel production (Figure 21). Consequently, while treatment with GHs reduces residual biomass of biofilms grown at either temperature, this reduction is only significant when biofilms are grown at 25°C. We will therefore switch to the use of clinical isolates from patients with chronic lung disease, which have been demonstrated to produce Pel and Psl at 37°C and are therefore more suitable for animal studies. Verification of the ability of these strains to form biofilms at 37°C is in progress.




Figure 21: Thermosensitivity of *P. aeruginosa* biofilm production. Left panel: Wrinkly biofilms are only produced in PA14 at 25°C. Right panel: Quantification of the biofilm biomass produced by *P. aeruginosa* at different temperatures and subsequently disrupted by GH treatment. \* indicates a significant decrease in biomass, with  $p \leq 0.05$  by ANOVA test.

**Major Task 3 - Subtasks 2, 3, 4:**

As reported above (Problems in Major Task 1 – Subtask 1), production of endotoxin free Ega3<sub>n</sub> required shifting to a new production system. This issue has now been resolved, and we are now able to perform both the IV injection in rabbits for the production of specific antibody and the intratracheal inoculation in mice for the pulmonary GH pharmacokinetic experiments. We are on track to finish all these studies within the coming 6 months.

**Changes that had a significant impact on expenditures**

*Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.*

No change with a significant impact on expenditures to be reported

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

*Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.*

**Significant changes in use or care of human subjects**

No use of human subjects in this grant

**Significant changes in use or care of vertebrate animals.**

No significant change in use or care of vertebrate animals to be reported

**Significant changes in use of biohazards and/or select agents**

No significant change in use of biohazards and/or select agents to be reported

**6. PRODUCTS:** List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

**Journal publications.** *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

**Publications**

1. Snarr BD, Baker P, Bamford NC, Sato Y, Liu H, Lehoux M, Gravelat FN, Ostapska H, Baistrocchi SR, Cerone RP, Filler EE, Parsek MR, Filler SG, Howell PL, and Sheppard DC. “Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.” PNAS, published online June 20, 2017, doi: 10.1073/pnas.1702798114.

**Books or other non-periodical, one-time publications.** *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: Author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

No publication in books or other non-periodical to be reported

**Other publications, conference papers, and presentations.** *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (\*) if presentation produced a manuscript.*

**Presentations**

1. P.L. Howell. *Microbial biofilms: Mechanisms to therapeutics*. SickKids Summer Student Seminar Program, Toronto, Ontario, June 22, 2017  
2. P.L. Howell. *Microbial biofilms: Mechanisms to therapeutics*. Ontario Public Health, Toronto, Ontario, May 22, 2017.



3. P. L. Howell. *Microbial biofilms: Mechanisms to therapeutics*. Understanding Biology through Structure, Santa Fe, New Mexico, May 13-17, 2017.
4. P.L. Howell. Glycoside hydrolases as therapeutics. Gordon Research Conference, Cellulases and other carbohydrate active enzymes, New Hampshire, July 24-28, 2017.
5. DC Sheppard. *Glycoside GHs as novel antibiofilm therapeutics*. US Department of Defense, CMDRP, Fort Detrick, Maryland, April 4, 2017.
6. DC Sheppard. *Glycoside GHs as novel antibiofilm therapeutics*. GlycoNET Network Centre of Excellence Annual General Meeting, Banff, Alberta, April 4, 2017.
7. DC Sheppard. *Aspergillus biofilm exopolysaccharide – from virulence factor to therapeutic target*. 29th Fungal Genetics Conference, Asilomar, California, March 19, 2017.
8. Sheppard DC, Invited Speaker, 29th Fungal Genetics Conference. Asilomar, California. "Breaking the mold: From host-pathogen interactions to novel therapeutics for Aspergillus disease." March 17 2017
9. Sheppard DC, Invited Speaker, IUBMB Frontiers in Glycoscience: Host-pathogen interactions. Taipei, Taiwan. *Biofilm exopolysaccharides at the host-pathogen interphase*. Dec 12 2016
10. Sheppard DC, Invited Speaker, Immunocompromised Host Society Meeting, Santiago, Chile. *Enhancing delivery of antifungals to pulmonary lesions – intracellular antifungals and antibiofilm therapeutics*. Nov 14 2016.

#### **Posters**

1. Snarr BD, Baker P, Bamford NC, Sato Y, Lui H, Lehoux M, Gravelat FN, Baistrocchi SR, Parsek MR, Filler SG, Howell PL, Sheppard DC. *Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity*. Trends in Medical Mycology Congress. Belgrade, Serbia. October 7, 2017
2. Bamford NC., Snarr BD., Gravelat FN., Little DJ., Le Mauff F., Lee MJ., Robinson H., Sheppard DC., Howell PL. *A novel glycoside hydrolase is required for galactosaminogalactan biosynthesis by Aspergillus fumigatus*. Canadian Glycobiology Network Symposium. Banff, Canada. May 11 2017.
3. P. Baker, H. Silver, P.J. Hill, M.J. Pestrak, M. Litvak, M. Post, M.R. Parsek, D.J. Wozniak, P.L. Howell. *Developing enzyme-based bacterial biofilm disruptors by targeting exopolysaccharides*. Canadian Glycomics Symposium 2017, Banff, Alberta, May 10-12, 2017.
4. N.C. Bamford, B.D. Snarr, F.N. Gravelat, D.J. Little, F. Le Mauff, M.J. Lee, H. Robinson, D.C. Sheppard, P.L. Howell. *A novel glycoside hydrolase is required for galactosaminogalactan biosynthesis by Aspergillus fumigatus*. Canadian Glycomics Symposium 2017, Banff, Alberta, May 10-12, 2017.
5. B.D. Snarr, P. Baker, N.C. Bamford, Y. Sato, H. Lui, M. Lehoux, S.R. Baistrocchi, S.G. Filler, P.L. Howell, D.C. Sheppard. *Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity against both bacteria and fungi*. RI-MUHC IDIGH Research Day 2017, Montreal, Quebec, April 21, 2017.

- **Website(s) or other Internet site(s)**

*List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.*

No dissemination of the results through a website to be reported

- **Technologies or techniques**

*Identify technologies or techniques that resulted from the research activities. In addition to a description of the technologies or techniques, describe how they will be shared.*

No new technology to be reported.

- **Inventions, patent applications, and/or licenses**

*Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.*

**Patent**

1. Howell PL, Baker P, Alnabelseya N, Sheppard DC, Bamford N, Little D, Snarr B, United States Provisional Patent application (No. 62/008,836) entitled “Soluble Bacterial and Fungal Proteins and Methods and Uses Thereof in Inhibiting and Dispersing Biofilm”. National phase filing in US, Canada, Europe, Australia and Japan occurred between Dec 2016 – Jan 2017 (Actual date depends on jurisdiction).

- **Other Products**

*Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment, and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:*

- *data or databases;*
- *biospecimen collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*

- *clinical interventions;*
- *new business creation; and*
- *other.*

No other product to be reported
---------------------------------

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

Provide the following information for: (1) PDs/Pis; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change."

Example:

*Name:* Mary Smith  
*Project Role:* Graduate Student  
*Researcher Identifier (e.g. ORCID ID):* 1234567  
*Nearest person month worked:* 5

*Contribution to Project:* Ms. Smith has performed work in the area of combined error-control and constrained coding.  
*Funding Support:* The Ford Foundation (Complete only if the funding support is provided from other than this award).

<i>Name:</i>	<i>P. Lynne Howell</i>
<i>Project Role:</i>	<i>PI</i>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>0000-0002-2776-062X</i>
<i>Nearest person month worked</i>	<i>12</i>
<i>Contribution to Project:</i>	<i>Responsible for the research performed at the Hospital for Sick Children.</i>
<i>Name:</i>	<i>Perrin Baker</i>
<i>Project Role:</i>	<i>Post Doctoral Fellow</i>
<i>Researcher Identifier (e.g. ORCID ID):</i>	<i>Not available</i>
<i>Nearest person month worked:</i>	<i>9</i>
<i>Contribution to Project:</i>	<i>Dr. Baker has been responsible for the development of yeast expression constructs and protein expression and purification. Dr. Baker left the Howell lab June, 2017</i>
<i>Name:</i>	<i>Ira Lacdao</i>
<i>Project Role:</i>	<i>Technician</i>

Researcher Identifier (e.g. ORCID ID): Not available  
Nearest person month worked: 8.25  
Contribution to Project: Ms Lacdao was hired in January 2017 and has been responsible for protein expression and purification since this time.

*Name:* Deepa Raju  
Project Role: Research Associate  
Researcher Identifier (e.g. ORCID ID): Not available  
Nearest person month worked: 0.25  
Contribution to Project: Dr Raju Lacdao was hired in September 2017 to replace Dr. Baker and will be responsible for the development of the ELISA and antibiotic potentiation experiments.

*Name:* Brian Hicks  
Project Role: Undergraduate Research Assistant  
Researcher Identifier (e.g. ORCID ID): Not available  
Nearest person month worked: 4  
Contribution to Project: Mr. Hicks assisted with the protein expression and purification

*Name:* Holly Silver  
Project Role: Research Assistant  
Researcher Identifier (e.g. ORCID ID): Not available  
Nearest person month worked: 1  
Contribution to Project: Ms Silver worked for Dr. Matt Parsek (University of Washington) and assisted with the antibiotic potentiation experiments reported.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

*If there is nothing significant to report during this reporting period, state "Nothing to Report."*

*If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.*

Dr. Perrin Baker left the Howell lab June, 210 to peruse a career in a small biotechnology company specializing in the development of anti-biofilm dressings. He was replaced September 2017 by Research Associate Dr. Deepa Raju.

**What other organizations were involved as partners?**

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”*

*Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.*

*Provide the following information for each partnership:*

Organization Name:

Location of Organization: (if foreign location list country)

Partner’s contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner’s facilities for project activities);*
- *Collaboration (e.g., partner’s staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and*
- *Other.*

University of Washington (Seattle, Washington) Collaboration with Dr. Parsek and members of his lab to help develop the Calgary biofilm device assay.

**8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:** For collaborative awards, independent reports are required from BOTH the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

**QUAD CHARTS:** If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.

# Development of New Therapeutics Targeting Biofilm Formation by the Opportunistic Pulmonary Pathogens *Pseudomonas aeruginosa* and *Aspergillus Fumigatus*

Grant Log #PR150786P1

Award #W81XWH-16-1-0284

PI: P. Lynne Howell Org: The Hospital for Sick Children

Award Amount: \$972,320


### Study/Product Aim(s)

- Aim 1. To characterize the ability of microbial hydrolases to enhance the activity of antimicrobial agents *in vitro*.
- Aim 2. Perform preliminary tolerability and pharmacokinetic studies of candidate hydrolases *in vivo*.
- Aim 3. To evaluate candidate hydrolases alone and in combination with antimicrobial agents in the treatment of experimental *A. fumigatus* and *P. aeruginosa* pulmonary infections *in vivo*.

### Approach

*A. fumigatus* and *P. aeruginosa* are two lung opportunistic pathogens that embed themselves in a biofilm, becoming therefore more resistant to drugs. We will demonstrate here the possibility to use four enzymes, two hydrolases from fungal origin, two from bacterial origin, to render microorganisms more susceptible to antimicrobials *in vivo*. We will also determine the concentration of hydrolases that is both efficient and well tolerated by the host. Our purpose is to generate data that will allow the start of clinical trials.

### Proposed mode of action of the hydrolases



Accomplishments in 2016-2017: Purification of all hydrolases. Enhancement of activity of several antifungal drugs on *A. fumigatus* biofilm when combined to the hydrolases in static culture and in dynamic culture. Showed an absence of toxicity of the hydrolases in immunocompetent mice. Production of anti-Ega3 antibody, and for all 4 hydrolases, validation of hydrolase detection in lung tissues.

### Timeline and Cost

Activities	CY	16	17	18	19
Specific Aim 1 - Major task 1					
Specific Aim 2 - Major task 2					
Specific Aim 2 - Major task 3					
Specific Aim 2 - Major task 4					
Specific Aim 3 - Major task 5					
Specific Aim 3 - Major task 6					
Specific Aim 3 - Major task 7					
<b>Estimated Budget (\$K)</b>		<b>\$123</b>	<b>\$327</b>	<b>\$310</b>	<b>\$212</b>

Updated: Oct 14, 2017

### Goals/Milestones

#### CY16 Goal:

- Express and purify Sph3<sub>n</sub>, Ega3<sub>n</sub>, PelA<sub>n</sub>, PslG<sub>n</sub> for Major Task 1

#### CY17 Goals/Milestones:

- Express and purify Sph3<sub>n</sub>, Ega3<sub>n</sub>, PelA<sub>n</sub>, PslG<sub>n</sub> for Major Task 1 – 5
- Test hydrolase combinations in checkerboard assay with antibiotics
- Determine concentration of hydrolases and their combinations in animal tissue samples.
- Identification of hydrolase-antimicrobial combination that synergize against *A. fumigatus* and *P. aeruginosa*.

- Evaluation of pulmonary toxicity of candidate hydrolase regimens
- Evaluation of pharmacokinetics of candidate hydrolase regimens

#### CY18 Goals/Milestones:

Express and purify Sph3<sub>n</sub>, Ega3<sub>n</sub>, PelA<sub>n</sub>, PslG<sub>n</sub> for Major Task 5 - 7

Develop variants of the candidate hydrolases (as required)

- Development of stable candidate hydrolases (as required)

#### CY19 Goals/Milestones:

Express and purify Sph3<sub>n</sub>, Ega3<sub>n</sub>, PelA<sub>n</sub>, PslG<sub>n</sub> for Major Task 5 – 7

Confirm efficacy of candidate hydrolase regimens for the treatment of

- acute infection with *A. fumigatus* and *P. aeruginosa*
- chronic infection with *A. fumigatus* and *P. aeruginosa*

- Demonstrate proof-of-concept for candidate hydrolases for use in treatment of *A. fumigatus* and *P. aeruginosa* infections

#### Budget Expenditure to Date:

Projected Expenditure: \$ 368,000

Actual Expenditure: \$ 339,144

9. **APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.



# Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity

Brendan D. Snarr<sup>a,b,1</sup>, Perrin Baker<sup>c,1</sup>, Natalie C. Bamford<sup>c,d,1</sup>, Yukiko Sato<sup>a,b</sup>, Hong Liu<sup>e</sup>, Mélanie Lehoux<sup>b</sup>, Fabrice N. Gravelat<sup>b</sup>, Hanna Ostapska<sup>a,b</sup>, Shane R. Baistrocchi<sup>a,b</sup>, Robert P. Cerone<sup>a,b</sup>, Elan E. Filler<sup>e</sup>, Matthew R. Parsek<sup>f</sup>, Scott G. Filler<sup>e,g</sup>, P. Lynne Howell<sup>c,d,2</sup>, and Donald C. Sheppard<sup>a,b,2</sup>

<sup>a</sup>Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada; <sup>b</sup>Department of Medicine, Infectious Diseases and Immunity in Global Health Program, Centre for Translational Biology, McGill University Health Centre, Montreal, QC, H4A 3J1, Canada; <sup>c</sup>Program in Molecular Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada; <sup>d</sup>Department of Biochemistry, University of Toronto, Toronto, ON, M5S 1A8, Canada; <sup>e</sup>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; <sup>f</sup>Department of Microbiology, University of Washington, Seattle, WA 98195; and <sup>g</sup>David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90024

Edited by Scott J. Hultgren, Washington University School of Medicine, St. Louis, MO, and approved March 30, 2017 (received for review March 2, 2017)

Galactosaminogalactan and Pel are cationic heteropolysaccharides produced by the opportunistic pathogens *Aspergillus fumigatus* and *Pseudomonas aeruginosa*, respectively. These exopolysaccharides both contain 1,4-linked *N*-acetyl- $\beta$ -galactosamine and play an important role in biofilm formation by these organisms. Proteins containing glycoside hydrolase domains have recently been identified within the biosynthetic pathway of each exopolysaccharide. Recombinant hydrolase domains from these proteins (Sph3<sub>h</sub> from *A. fumigatus* and PelA<sub>h</sub> from *P. aeruginosa*) were found to degrade their respective polysaccharides in vitro. We therefore hypothesized that these glycoside hydrolases could exhibit antibiofilm activity and, further, given the chemical similarity between galactosaminogalactan and Pel, that they might display cross-species activity. Treatment of *A. fumigatus* with Sph3<sub>h</sub> disrupted *A. fumigatus* biofilms with an EC<sub>50</sub> of 0.4 nM. PelA<sub>h</sub> treatment also disrupted preformed *A. fumigatus* biofilms with EC<sub>50</sub> values similar to those obtained for Sph3<sub>h</sub>. In contrast, Sph3<sub>h</sub> was unable to disrupt *P. aeruginosa* Pel-based biofilms, despite being able to bind to the exopolysaccharide. Treatment of *A. fumigatus* hyphae with either Sph3<sub>h</sub> or PelA<sub>h</sub> significantly enhanced the activity of the antifungals posaconazole, amphotericin B, and caspofungin, likely through increasing antifungal penetration of hyphae. Both enzymes were noncytotoxic and protected A549 pulmonary epithelial cells from *A. fumigatus*-induced cell damage for up to 24 h. Intratracheal administration of Sph3<sub>h</sub> was well tolerated and reduced pulmonary fungal burden in a neutropenic mouse model of invasive aspergillosis. These findings suggest that glycoside hydrolases can exhibit activity against diverse microorganisms and may be useful as therapeutic agents by degrading biofilms and attenuating virulence.

biofilm | *Aspergillus* | *Pseudomonas* | therapeutics | exopolysaccharide

The mold *Aspergillus fumigatus* and the Gram-negative bacterium *Pseudomonas aeruginosa* are opportunistic pathogens that cause pulmonary infection in immunocompromised patients and individuals who suffer from chronic lung diseases such as cystic fibrosis and bronchiectasis. *A. fumigatus* is the second most common nosocomial fungal infection (1), and ~10% of all nosocomial bacterial infections are caused by *P. aeruginosa* (2). Mortality associated with *P. aeruginosa* infections is high (3) and has increased with the emergence of multi- and even pan-resistance to antibiotics (3, 4). Similarly, invasive aspergillosis is associated with mortality rates of up to 50% (5), and increasing rates of antifungal resistance have been reported worldwide (6). These factors underscore the urgent need for new effective therapies for these infections.

Although *A. fumigatus* and *P. aeruginosa* are members of different taxonomic kingdoms, both produce biofilms that constitute a protective lifestyle for the organism. Biofilms are complex communities of microorganisms that grow embedded in an extracellular matrix composed of DNA, protein, and

exopolysaccharide (7). Biofilm formation provides a significant advantage to these organisms because the matrix mediates adherence to host cells (8, 9) and aids in the resistance to both antimicrobial agents (10, 11) and host-immune defenses (12, 13). *A. fumigatus* biofilm formation depends on the cationic polysaccharide galactosaminogalactan (GAG), a heteroglycan composed of  $\alpha$ 1,4-linked galactose and *N*-acetyl- $\beta$ -galactosamine (GalNAc) that is partially deacetylated (14, 15). In comparison, *P. aeruginosa* has the genetic capacity to produce three biofilm exopolysaccharides: alginate, Psl and Pel (16). GAG shares several similarities with Pel, which has been identified as a cationic heteroglycan composed of 1,4-linked GalNAc and *N*-acetyl- $\beta$ -glucosamine (GlcNAc) (17). Like GAG, the cationic nature of Pel results from partial deacetylation of the polymer (17). Most clinical and environmental isolates of *P. aeruginosa* use Pel and Psl during biofilm formation (18). Alginate is dispensable for biofilm formation and is only observed in chronic pulmonary infection when strains switch to a mucoid phenotype (18, 19).

Strains of *Aspergillus* and *P. aeruginosa* with impaired GAG, or Pel and Psl biosynthesis exhibit attenuated virulence (20, 21), suggesting that targeting these exopolysaccharides may be a

## Significance

The production of biofilms is an important strategy used by both bacteria and fungi to colonize surfaces and to enhance resistance to killing by immune cells and antimicrobial agents. We demonstrate that glycoside hydrolases derived from the opportunistic fungus *Aspergillus fumigatus* and Gram-negative bacterium *Pseudomonas aeruginosa* can be exploited to disrupt preformed fungal biofilms and reduce virulence. Additionally, these glycoside hydrolases can be used to potentiate antifungal drugs by increasing their hyphal penetration, to protect human cells from fungal-induced injury, and attenuate virulence of *A. fumigatus* in a mouse model of invasive aspergillosis. The findings of this study identify recombinant microbial glycoside hydrolases as promising therapeutics with the potential for antibiofilm activity against pathogens across different taxonomic kingdoms.

Author contributions: B.D.S., P.B., N.C.B., P.L.H., and D.C.S. designed research; B.D.S., P.B., N.C.B., Y.S., H.L., M.L., F.N.G., H.O., S.R.B., R.P.C., and E.E.F. performed research; M.R.P. contributed new reagents/analytic tools; B.D.S., P.B., N.C.B., Y.S., H.L., M.L., F.N.G., S.R.B., S.G.F., P.L.H., and D.C.S. analyzed data; and B.D.S., P.B., N.C.B., M.R.P., S.G.F., P.L.H., and D.C.S. wrote the paper.

Conflict of interest statement: A patent has been filed describing the utility of the glycoside hydrolases as antibiofilm therapeutics (CA2951152 A1, WO2015184526 A1). B.D.S., P.B., N.C.B., P.L.H., and D.C.S. are listed as inventors.

This article is a PNAS Direct Submission.

<sup>1</sup>B.D.S., P.B., and N.C.B. contributed equally to this work.

<sup>2</sup>To whom correspondence may be addressed. Email: don.sheppard@mcgill.ca or howell@sickkids.ca.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1702798114/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1702798114/-DCSupplemental).



# Development of New Therapeutics Targeting Biofilm Formation by the Opportunistic Pulmonary Pathogens *Pseudomonas aeruginosa* and *Aspergillus Fumigatus*



Grant Log #PR150786P1

Award #W81XWH-16-1-0284

PI: P. Lynne Howell Org: The Hospital for Sick Children


Award Amount: \$972,320

## Study/Product Aim(s)

- Aim 1. To characterize the ability of microbial hydrolases to enhance the activity of antimicrobial agents *in vitro*.
- Aim 2. Perform preliminary tolerability and pharmacokinetic studies of candidate hydrolases *in vivo*.
- Aim 3. To evaluate candidate hydrolases alone and in combination with antimicrobial agents in the treatment of experimental *A. fumigatus* and *P. aeruginosa* pulmonary infections *in vivo*.

## Approach

*A. fumigatus* and *P. aeruginosa* are two lung opportunistic pathogens that embed themselves in a biofilm, becoming therefore more resistant to drugs. We will demonstrate here the possibility to use four enzymes, two hydrolases from fungal origin, two from bacterial origin, to render microorganisms more susceptible to antimicrobials *in vivo*. We will also determine the concentration of hydrolases that is both efficient and well tolerated by the host. Our purpose is to generate data that will allow the start of clinical trials.



Accomplishments in 2016-2017: Purification of all hydrolases. Enhancement of activity of several antifungal drugs on *A. fumigatus* biofilm when combined to the hydrolases in static culture and in dynamic culture. Showed an absence of toxicity of hydrolases in immunocompetent mice. Production of anti-Ega3 antibody, and for all 4 hydrolases, validation of hydrolase detection in lung tissues.

## Timeline and Cost

Activities	CY	16	17	18	19
Specific Aim 1 - Major task 1					
Specific Aim 2 - Major task 2					
Specific Aim 2 - Major task 3					
Specific Aim 2 - Major task 4					
Specific Aim 3 - Major task 5					
Specific Aim 3 - Major task 6					
Specific Aim 3 - Major task 7					
<b>Estimated Budget (\$K)</b>		<b>\$123</b>	<b>\$327</b>	<b>\$310</b>	<b>\$212</b>

Updated: Oct 14, 2017

## Goals/Milestones

### CY16 Goal:

- Express and purify Sph<sub>3h</sub>, Ega<sub>3h</sub>, PelA<sub>h</sub>, PslG<sub>h</sub> for Major Task 1

### CY17 Goals/Milestones:

- Express and purify Sph<sub>3h</sub>, Ega<sub>3h</sub>, PelA<sub>h</sub>, PslG<sub>h</sub> for Major Task 1 – 5
- Test hydrolase combinations in checkerboard assay with antibiotics
- Determine concentration of hydrolases and their combinations in animal tissue samples.
- Identification of hydrolase-antimicrobial combination that synergize against *A. fumigatus* and *P. aeruginosa*.
- Evaluation of pulmonary toxicity of candidate hydrolase regimens
- Evaluation of pharmacokinetics of candidate hydrolase regimens

### CY18 Goals/Milestones:

- Express and purify Sph<sub>3h</sub>, Ega<sub>3h</sub>, PelA<sub>h</sub>, PslG<sub>h</sub> for Major Task 5 - 7
- Develop variants of the candidate hydrolases (as required)
- Development of stable candidate hydrolases (as required)

### CY19 Goals/Milestones:

- Express and purify Sph<sub>3h</sub>, Ega<sub>3h</sub>, PelA<sub>h</sub>, PslG<sub>h</sub> for Major Task 5 – 7
- Confirm efficacy of candidate hydrolase regimens for the treatment of
  - acute infection with *A. fumigatus* and *P. aeruginosa*
  - chronic infection with *A. fumigatus* and *P. aeruginosa*
- Demonstrate proof-of-concept for candidate hydrolases for use in treatment of *A. fumigatus* and *P. aeruginosa* infections

### Budget Expenditure to Date:

Projected Expenditure: \$ 368,000

Actual Expenditure: \$ 339,144